AstraZeneca To Invest More Than $500 M into Mfg and Research in France
AstraZeneca is investing more than $500 million over five years in France in several manufacturing and research and development (R&D) projects, including a $230-million investment to expand its manufacturing site in Dunkirk, France.
The Dunkirk facility is dedicated to the development, manufacturing and supply of aerosol products. The company says the expansion is for the upcoming launch of new products for treating asthma and chronic obstructive pulmonary disease as well as to meet increased sales volumes in China. Nearly 100% (99.9%) of products made at the site are exported. The $230-million investment through 2025 is for an autonomous assembly line, two assembly and packaging lines, and modernization of existing equipment and infrastructure.
AstraZeneca also bought back its packaging and distribution center for oral solid dose drug products in Reims, France, which it had sold in 2017 to Avara Pharmaceutical Services. The facility will continue to package and distribute drugs from AstraZeneca for the French and international markets. In 2019, the Reims site packaged 25 million boxes of medication through seven automated lines. It also distributed 22 million boxes of medicines in France and 19 million internationally.
The company also plans to invest $275 million for R&D in France and will further invest in an European Innovation hub in Paris.